A couple of observations re the rate of decline on the ALSFRS-R:
1) It’s subjective and, as such, prone to greater variation based on the patient self-reports. 2) A decline 0.77 points per month on the ALSFRS-R is a far superior outcome than that achieved by any of the other HEALEY trial regimens, as shown in the following chart: I think the survival data is the most telling and, as the data showing why the drug works builds, the investment thesis becomes more and more compelling. E ven for a large pharma.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)